Altimmune’s pemvidutide shows promising Phase IIb MASH results; see key benefits, risks, and a bullish outlook. Read here for ...

Repligen (RGEN) is a top bioprocessing stock pick for long-term investors. It has strong balance sheet and recurring organic ...

Citigroup shows tangible book growth, better RoTCE, broad Q3 revenue gains, valuation changes and key execution risks. Find ...

Shares U.S. Broker-Dealers & Securities Exchanges ETF is a top non-tech growth pick, offering strong returns. See more on IAI ...

Read here for an analysis of Boise Cascade (BCC) stock's market resilience, high vertical integration, and financial outlook ...

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...

Alexandra Gorewicz, VP & Director, Active Fixed Income Portfolio Management, TD Asset Management, talks about what investors ...

The Fed continues to navigate a challenging backdrop: a steadily cooling labor market alongside inflation that remains ...

The iShares MSCI Chile ETF (ECH) is outperforming emerging markets and showing breakout potential ahead of elections. See ...

Meta Platforms delivers long-term compounding, AI monetization, strong Q3 growth and higher CAPEX with upside potential.

Arch Capital Group shows strong fundamentals, solid Q3 benefits, steady profitability and disciplined buybacks at value ...

ORIX Corp stock is rated a Buy after a strong Q2, a 70% profit surge, and raised FY26 guidance. Here's what investors need to ...